Robbins Geller says the Exchange Act case targets Grail and certain current and former executives over alleged misstatements about the NHS-Galleri trial’s chances of meeting its primary endpoint.
Investors who purchased or acquired GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 have until Tuesday, August 4, 2026 to seek appointment as lead plaintiff in a securities class action filed in the Northern District of California. The case, Robbins v. Grail, Inc., No. 26-cv-05428, alleges violations of the Securities Exchange Act of 1934 by Grail and certain of its current and former executive officers. The complaint focuses on statements tied to Grail’s NHS-Galleri trial, which was designed to show a reduction in late-stage cancers among people who received the Galleri test versus those who did not. It alleges Grail gave investors a false impression that it had reliable information supporting the likelihood of achieving the study’s primary endpoint of a statistically significant reduction in Stage III-IV cancers, while concealing adverse facts that reduced the chances of that outcome. The suit further alleges management’s confidence, following positive top-line results from the trial’s first screening round and the Pathfinder studies, was misplaced because unreleased topline data and other information since the study began suggested three years would be insufficient to demonstrate the endpoint. On February 19, 2026, Grail said the NHS-Galleri trial did not observe its primary endpoint of a statistically significant Stage III-IV reduction and indicated that longer follow-up was probably needed to compare the study arms adequately. Grail shares fell more than 50% on that news, according to the complaint.